Inositols in PCOS
Open accessThe DOI matches its Crossref record; 143 of the 147 references it cites were found in a registry or an index.
Abstract
(1) Background: Myoinositol (MI) and D-chiro-inositol (DCI) are involved in a number of biochemical pathways within oocytes having a role in oocyte maturation, fertilization, implantation, and post-implantation development. Both inositols have a role in insulin signaling and hormonal synthesis in the ovaries. (2) Methods: Literature search (with key words: inositols, myo-inositol, d-chiro-inositol, PCOS) was done in PubMed until Sept. 2020 and 197 articles were identified, of which 47 were of clinical trials (35 randomized controlled trials). (3) Results: Many studies have demonstrated that in patients with polycystic ovarian syndrome (PCOS) MI treatment improved ovarian function and fertility, decreased the severity of hyperandrogenism including acne and hirsutism, positively affected metabolic aspects, and modulated various hormonal parameters deeply involved in the reproductive axis function and ovulation. Thus treating with MI has become a novel method to ameliorate PCOS symptoms, improve spontaneous ovulation, or induce ovulation. The current review is focused on the effects of MI and DCI alone or in combination with other agents on the pathological features of PCOS with focus on insulin resistance and adverse metabolic outcomes. (4) Conclusions: The available clinical data suggest that MI, DCI, and their combination in physiological ratio 40:1 with or without other compound could be beneficial for improving metabolic, hormonal, and reproductive aspects of PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 (a) Effects of myoinositol and D-chiroinositol on glucose metabolism in PCOS (adapted from [68]). (b) Effects of myoinositol and D-chiroinositol on hormonal synthesis in PCOS.](https://figures.cochat.ai/paper-figures/9dd0bedcafd0485a835f08372099aad1/inositols-in-pcos-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“On the other hand, insulin resistance (IR) has a central role in its pathogenesis [5–7].”
From Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Papaleo, E., Unfer, V., Baillargeon, J.-P., Fusi, F., Occhi, F., & De Santis, L. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.01.088 · Cited by 197 · cited 1×
“The trials assessing this combination show improved reproductive [100], hormonal, and metabolic disturbances in PCOS patients [95,97,108,123].”
BackgroundRetracted- Retracted
Pacchiarotti, A., Carlomagno, G., Antonini, G., & Pacchiarotti, A. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1101444 · Cited by 111
RetractedRETRACTED: Treatment of hirsutism with myo-inositol: a prospective clinical study
Minozzi, M., D'Andrea, G., & Unfer, V. (2008) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60248-9 · Cited by 56 · cited 2×
“Some studies have demonstrated that MI treatment in patients with PCOS improved ovarian function and fertility [98–109], decreased the severity of hyperandrogenism, acne, and hirsutism [78,96,102], and positively affected metabolic parameters and modulated various hormonal parameters deeply involved in the reproductiv…”
BackgroundMethodRetracted(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458 · cited 1×
“The patients with PCOS both with and without obesity have higher prevalence of insulin resistance compared to healthy controls [19], although insulin resistance is more severe in obese subjects [20].”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 2×
“The use of Rotterdam criteria is advised by the two recent guidelines [7,9] both recognizing that Androgen Excess Society (AES) [1] criteria may correspond better to the pathogenesis of this disorder, as the AES emphasizes the importance Molecules 2020, 25, 5566; doi:10.3390/molecules25235566 www.mdpi.com/journal/mole…”
MethodInfluentialProfound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967 · cited 1×
“It affects muscle and fat tissue and the liver, but not the polycystic ovary itself [39,40].”
BackgroundTeede, H. J., Misso, M. L., Costello, M. F., Dokras, A., Laven, J., Moran, L., Piltonen, T., Norman, R. J., & the International PCOS Network (2018) · Clinical Endocrinology · doi:10.1111/cen.13795 · Cited by 1,823
Research works printed but not linked: 4
- Ciotta L. Iozza I. Rubbino G. Iemmola A. Lizzio I. Teodoro M.C. Palumbo M. Treatment of hyperandrogenism by myo-inositol Proceedings of the 14th World Congress of Gynecological Endocrinology Firenze, Italy 4–7 March 2010
- Di Berardino O.M. Monteleone P. Valentino V. Ruggiero M. Papini F. Cela V. Artini P.G. Genazzani A.R. Myo-inositol administration in pcos patients after IVF Proceedings of the 14th World Congress of Gynecological Endocrinology Firenze, Italy 4–7 March 2010
- Papaleo E. De Santis L. Baillargeon J. Zacche M. Fusi F. Brigante C. Ferrari A. Comparison of myo-inositol plus folic acid vs clomiphene citrate for first line treatment in women with polycystic ovary syndrome Proceedings of the 24th Annual Meeting of ESHRE Barcelona, Spain 6–9 July 2008
- Genazzani A. Expert’s opinion: Integrative treatment with inositols and lipoic acid for insulin resistance of PCOS. Gynecol Reprod. Endocrinol. Metab. 2020 1 146 157
Cited by
Contreras-Bolívar, V., García-Fontana, B., García-Fontana, C., & Muñoz-Torres, M. (2021) · Nutrients · doi:10.3390/nu13103491 · Cited by 226
Mitochondrial Dysfunction and Chronic Inflammation in Polycystic Ovary Syndrome
Dabravolski, S. A., Nikiforov, N. G., Eid, A. H., Nedosugova, L. V., Starodubova, A. V., Popkova, T. V., Bezsonov, E. E., & Orekhov, A. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083923 · Cited by 207
Calcaterra, V., Verduci, E., Cena, H., Magenes, V. C., Todisco, C. F., Tenuta, E., Gregorio, C., De Giuseppe, R., Bosetti, A., Di Profio, E., et al. (2021) · Nutrients · doi:10.3390/nu13061848 · Cited by 183
“Among them, inositol [166,167] has been shown to provide benefits for subjects with PCOS, improving IR and reducing the secretion of triglycerides.”
BackgroundPolycystic ovarian syndrome-current pharmacotherapy and clinical implications
Rashid, R., Mir, S. A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2021.11.009 · Cited by 156
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
“However, 25% to 75% of patients treated with myo-Ins may still be resistant to treatment [171].”
BackgroundSelf-citationGreff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyirády, P., Ács, N., et al. (2023) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-023-01055-z · Cited by 143
Bhalla, N., Ingle, N., Patri, S. V., & Haranath, D. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.07.075 · Cited by 129
Effect and mechanism of berberine against polycystic ovary syndrome
Zhang, S., Zhou, J., Gober, H.-J., Leung, W. T., & Wang, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111468 · Cited by 82
Questioning PCOS phenotypes for reclassification and tailored therapy
Myers, S. H., Russo, M., Dinicola, S., Forte, G., & Unfer, V. (2023) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2023.08.005 · Cited by 74
Polycystic ovary syndrome: Current scenario and future insights
Kulkarni, S., Gupta, K. A., Ratre, P., Mishra, P. K., Singh, Y., Biharee, A., & Thareja, S. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103821 · Cited by 66
Polycystic ovary syndrome: Causes, symptoms, pathophysiology, and remedies
Chaudhuri, A. (2023) · Obesity Medicine · doi:10.1016/j.obmed.2023.100480 · Cited by 72
Melatonin and Myo-Inositol: Supporting Reproduction from the Oocyte to Birth
Russo, M., Forte, G., Oliva, M. M., Laganà, A. S., & Unfer, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168433 · Cited by 51
“Therefore myo-ins supplementation is useful in the treatment of PCOS, as it is an important constituent of follicular microenvironment, mediates FSH signaling and promotes oocyte development and maturation [42].”
BackgroundInositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies
Lepore, E., Lauretta, R., Bianchini, M., Mormando, M., Lorenzo, C. D., & Unfer, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136796 · Cited by 50
“Indeed, several studies confirmed the correlation between altered inositol metabolism and metabolic changes, including diabetes, obesity, and metabolic syndrome [14,64,80].”
BackgroundNovel Chemical and Biological Insights of Inositol Derivatives in Mediterranean Plants
Siracusa, L., Napoli, E., & Ruberto, G. (2022) · Molecules · doi:10.3390/molecules27051525 · Cited by 46
“Myo-ins alone or in combination with D-chiro-ins showed to exert an effect against PCOS syndrome improving metabolic and ovarian function [66], especially in the 40:1 ratio exactly what we can find in the plasma [67,68] (Figure 6).”
BackgroundScarfò, G., Daniele, S., Fusi, J., Gesi, M., Martini, C., Franzoni, F., Cela, V., & Artini, P. G. (2022) · Biomedicines · doi:10.3390/biomedicines10061305 · Cited by 45
Chauvin, S. (2025) · Biomolecules · doi:10.3390/biom15070923 · Cited by 40
“On the other hand, myo-inositol, a highly studied nutritional supplement, has demonstrated efficacy in improving insulin sensitivity and oocyte quality by facilitating glucose uptake through GLUT4 translocation and enhancing FSH-induced aromatase activity [186].”
A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes?
Unfer, V., Dinicola, S., & Russo, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076213 · Cited by 34
“Despite the chemical similarities and their synergistic effect on insulin sensitivity, they exert different effects on the ovary [37].”
BackgroundBrown Adipose Tissue and Novel Management Strategies for Polycystic Ovary Syndrome Therapy
Zhang, Q., Ye, R., Zhang, Y., Fan, C.-C., Wang, J., Wang, S., Chen, S., & Liu, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.847249 · Cited by 34
Kalyanaraman, R., & Pal, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094905 · Cited by 30
“Metformin is the prototype of insulin sensitizing drugs that is commonly utilized in PCOS management although accruing data in recent years provide reassuring evidence of therapeutic efficacy as well as safety of isomers of inositol (carbocyclic polyols) in improving insulin sensitivity in PCOS populations [17].”
BackgroundArefhosseini, S., Roshanravan, N., Tutunchi, H., Rostami, S., Khoshbaten, M., & Ebrahimi‐Mameghani, M. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1092544 · Cited by 29
Tabatabaie, M., Amiri, S., Jahromi, M. G., Sene, A. A., Zandieh, Z., Mehdizadeh, M., & Amjadi, F. (2022) · Molecular Biology Reports · doi:10.1007/s11033-021-06833-9 · Cited by 25
Jethaliya, H., Gajjar, N., Patel, V., Deshpande, S., & Patel, R. (2022) · Reproductive Sciences · doi:10.1007/s43032-022-00933-y · Cited by 17
“Results of such studies suggest the improvement in IR, menstrual irregularities, acne score, and various endocrine as well as metabolic parameters [23].”
Lete, I., Martínez, A., Lasaga, I., Centurión, E., & Vesga, A. (2024) · Gynecological Endocrinology · doi:10.1080/09513590.2023.2301554 · Cited by 28
“In addition, MYO increases cellular glucose uptake and DCI increases glycogen synthesis, leading to a decrease in insulin resistance [48].”
Pustotina, O. A., Myers, S. H., Unfer, V., & Rasulova, I. (2024) · Gynecologic and Obstetric Investigation · doi:10.1159/000536163 · Cited by 24
“Furthermore, it has been suggested that high levels of glucose may induce MI de fi ciency, as IR and hyperglycemia are through to affect the cellular isomeric ratio between MI and DCI [30, 31].”
BackgroundKamal, D. A. M., Ibrahim, S. F., Ugusman, A., & Mokhtar, M. H. (2022) · Antioxidants · doi:10.3390/antiox11101879 · Cited by 20
“Previously, inositol, a naturally occurring substance found primarily in fruits, grains, and beans, was shown to be effective in treating metabolic and reproductive disorders in PCOS women [26,27].”
BackgroundTreatment with Myo-Inositol Does Not Improve the Clinical Features in All PCOS Phenotypes
Unfer, V., Russo, M., Aragona, C., Bilotta, G., Oliva, M. M., & Bizzarri, M. (2023) · Biomedicines · doi:10.3390/biomedicines11061759 · Cited by 18
“The supplementation of myo-Ins in PCOS patients undergoing assisted reproductive technique (ART) programs improves oocyte development and maturation [10].”
BackgroundBila, J. S., Dotlić, J., Andjić, M., Ivanović, K., Micić, J., Tulić, L., Pupovac, M., Stojnić, J., Vuković, I., & Ivanovic, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14165642 · Cited by 25
“On the other hand, GLP-1 receptor agonists may be linked to more frequent occurrence of nausea and headache than metformin, but no noteworthy differences in the occurrence of other adverse effects were registered so far [45,46,53,54].”
Béresniak, A., Russo, M., Forte, G., Laganà, A. S., Oliva, M. M., Aragona, C., Chiàntera, V., & Unfer, V. (2023) · Scientific Reports · doi:10.1038/s41598-023-44055-0 · Cited by 13
Aghajani, T., Arefhosseini, S., Ebrahimi‐Mameghani, M., & Safaralizadeh, R. (2024) · Food Science & Nutrition · doi:10.1002/fsn3.4267 · Cited by 13
“In PCOS, supplementation with MI significantly reduced HOMA-IR, metabolic, and hormonal factors (Kamenov & Gateva, 2020).”
MethodThe "asthma-polycystic ovary overlap syndrome" and the therapeutic role of myo-inositol
Guarnieri, G., Iervolino, M., Cavallone, S., Unfer, V., & Vianello, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24086959 · Cited by 11
Džafić, A., & Žuljević, S. O. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.102570 · Cited by 15
Ramírez-Martínez, L., Palafox-Gómez, C., Porchia, L. M., & López‐Bayghen, E. (2024) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/j.ceog5103057 · Cited by 11
“Pharmacological interventions, as mentioned above, have shown promise in reducing symptoms associated with PCOS; however, pharmacological interventions have been reviewed before [53,55,56].”
BackgroundEffects of myo-inositol plus folic acid on ovarian morphology and oocyte quality in PCOS mouse model
Haghighi, M., Mehdizadeh, M., Amjadi, F., Zandieh, Z., Najafi, M., Artimani, T., Mohammadi, F., & Mehdizadeh, R. (2023) · Zygote · doi:10.1017/s0967199422000557 · Cited by 13
Bioactivity of Inositol Phosphates
Vučenik, I. (2021) · Molecules · doi:10.3390/molecules26165042 · Cited by 10
“Moreover, because of the role of insulin signaling and hormonal synthesis in the ovaries, and involvement of Ins in a number of biochemical pathways within oocytes, the beneficial effect of Ins, D-chiro-inositol, and their combination was shown in polycystic ovarian syndrome (PCOS) by improving the metabolic, hormonal…”
BackgroundPayer, J., Jackuliak, P., Kužma, M., Džupon, M., & Vaňuga, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1067029 · Cited by 15
“Many authors described the importance of myo-Ins in the ovarian physiology, particularly in women with polycystic ovary syndrome (PCOS), which often exhibit irregular menstrual cycle due to alterations in the oogenesis and oocyte maturation, other than a hormonal unbalance (53, 54).”
BackgroundDinicola, S., Unfer, V., Soulage, C. O., Yap‐Garcia, M. I. M., Bevilacqua, A., Benvenga, S., Barbaro, D., Wdowiak, A., Nordio, M., Dewailly, D., et al. (2024) · Gynecologic and Obstetric Investigation · doi:10.1159/000536081 · Cited by 11
“Insulin Signaling D -Chiro-Ins plays an important role in insulin signaling by decreasing systemic insulin levels by facilitating glycogen storage [16].”
Self-citationPrebiotics, Probiotics, and Postbiotics for Acne Vulgaris: A Systematic Review
Warp, P. V., Bilik, S. M., Ferrari, L. M., & Keri, J. E. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01659-4 · Cited by 8
“Myoinositol regulates hormonal influences for acne mainly by decreasing testosterone levels [47].”
Lin, Y., Liu, X., Li, X., Tang, Q., Meng, F., & Chen, W. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220508180611 · Cited by 10
Phytotherapy in Polycystic Ovary Syndrome (PCOS) Management: A Systematic Review
Mohamed, S. S., Allam, A. T., Elalfy, A., El‐Shiekh, R. A., Reda, A. M., & Hafeez, M. S. A. E. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202500982 · Cited by 6
“Using two inositol isomers, myo -inositol (MI) and d-chiro-inositol (DCI), offers a promising therapeutic approach for managing PCOS [125, 106].”
Min, M., Afzal, N., Maloh, J., Dulai, A. S., Ahmad, N., Pinzauti, D., & Sivamani, R. K. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01411-4 · Cited by 8
“Myoino-sitol regulates hormonal influences for acne [23].”
A bitter pill to swallow: adjustments to oral contraceptive pill use in polycystic ovary syndrome
Calcagno, M., Serra, P., Etrusco, A., Margioula‐Siarkou, C., Terzic, S., Giannini, A., Garzon, S., Ferrari, F. G., Dellino, M., & Laganà, A. S. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2371977 · Cited by 8
“When contraception is not required and the patient with PCOS exhibits clinical manifestation related to EMS, lifestyle changes and/or insulin-sensitizer agents have a crucial therapeutic role [55–57].”
Scannell, N., Mantzioris, E., Rao, V. S., Pandey, C., Ee, C., Mousa, A., Moran, L., & Villani, A. M. (2023) · Biomedicines · doi:10.3390/biomedicines11123349 · Cited by 12
Stereoselective synthesis of novel bis-homoinositols with bicyclo[4.2.0]octane motifs
Barotcu, A. Z., Karanfil, A., Şahi̇n, E., & Kelebekli, L. (2022) · Carbohydrate Research · doi:10.1016/j.carres.2022.108611 · Cited by 5
D-Chiro-Inositol in Endometrial Hyperplasia: A Pilot Study
Porcaro, G., Bilotta, G., Capoccia, E., Espinola, M. S. B., & Aragona, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210080 · Cited by 5
“Over the years, DCI has been used in the clinical practice of several clinical pictures, including insulin resistance and PCOS [19,21,31].”
BackgroundAragona, C., Russo, M., Myers, S. H., Espinola, M. S. B., Bilotta, G., & Unfer, V. (2025) · Health Economics Review · doi:10.1186/s13561-025-00609-8 · Cited by 5
Chaudhary, A., More, A., Choudhary, N., Barai, J., & Wadhe, T. (2025) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_166_25 · Cited by 3
“[8]”
Aziz, M. (2023) · Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal · doi:10.26685/urncst.473 · Cited by 6
Khan, R. B., Sarosh, M., & Anwer, S. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2216121 · Cited by 2
Plasma metabolomic profiling during peri‐parturition in healthy Thoroughbred mares
Li, J., Matsumoto, T., Liu, H., Li, C., MURASE, H., Yamamoto, Y., & Nagaoka, K. (2025) · Equine Veterinary Journal · doi:10.1111/evj.14550 · Cited by 2
Nutrition interventions in women with polycystic ovary syndrome: a systematic review
Akbaş, E., Samancı, M., & Öztürk, Y. E. (2026) · European Journal of Nutrition · doi:10.1007/s00394-026-04030-7 · Cited by 3
Investigation of Phytoestrogens Found in Sesame Seeds via Computational and Translational Approaches
Haider, F., Riaz, S., Shakeel, R., Hafeez, K., Qureshi, U. Z., & Rehman, R. (2023) · BioScientific Review · doi:10.32350/bsr.54.05 · Cited by 2
Abdullah, M. R., & Alabassi, H. M. (2024) · Karbala International Journal of Modern Science · doi:10.33640/2405-609x.3361 · Cited by 4
Hamed, B. M., El-Sayed, Y. A. E., El-Ghazawy, S. S., & Mohamed, A. I. (2023) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2023.287312 · Cited by 2
Effects of Chromium, Inositol and Resistant Starch Supplementation In Pcos: A Systematic Review
Krishnan, N., & Velraja, S. (2023) · Biomedical and Biotechnology Research Journal (BBRJ) · doi:10.4103/bbrj.bbrj_21_23 · Cited by 2
PCOS and common androgen abnormalities in adolescents
Burgert, T. S., & Paprocki, E. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-10512-8.00028-x · Cited by 3
Target therapy of polycystic ovary syndrome
Turchinets, A. I., Uvarova, E. V., Khashchenko, K. E. P., & Kumykova, Z. K. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-060 · Cited by 1
Metabolic disorders and infertility
Дикке, Г. Б. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-1-06 · Cited by 12
Upadhyay, S., Mazumder, A., & Das, S. (2025) · Current Pharmaceutical Design · doi:10.2174/0113816128382284250822045319 · Cited by 1
Jiang, Q. Y., Pu, D., Hu, Y., Wu, R., Jiang, C., Yuan, S., Zhu, X., & Xu, L. (2025) · Medicine · doi:10.1097/md.0000000000046163 · Cited by 1
“[34] These results suggest that PCOS is associated with chronic low-grade inflammation, obesity, and insulin resistance.”
Polycystic Ovary Syndrome: A Therapeutic Challenge
León, M. F. C., Miguel, G. L. S., Santos, D. D. G., Acuña, R. I. C., Fernández, J. C. S., Mendoza, A. P. C., Loor, C. O. L., Vélez, V. C. T., Velez, L., & Cepeda, S. P. D. (2025) · Obstetrics and gynecology. · doi:10.5772/intechopen.1013041 · Cited by 1
Wei, S., Qin, T. G., Li, Y., Zhang, D., Liu, L. A., Wei, L., & Zhao, R. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04970-7 · Cited by 1
Mashhadi, F., Ghaebi, N. K., Rakhshandeh, H., Khadem‐Rezaiyan, M., Roudi, F., & Nematy, M. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-025-01867-0 · Cited by 3
“%) being treatment-resistant, particularly those with obesity and hyperandrogenism [16, 17].”
Wang, J., Yang, Y., Wang, Z. X., Li, F., Shi, Z., Gao, T., & Chang, H. (2026) · Frontiers in Global Women s Health · doi:10.3389/fgwh.2026.1836617 · Cited by 1
Use of myo-inositol in the treatment of PCOS symptoms in adolescents
Pkhaladze, L., Unfer, V., & Dewailly, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00001-7 · Cited by 3
Cantelmi, T., & Lorenzo, C. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91673-8.00003-0 · Cited by 2
Gypakis, A., Adelt, S., Lemoine, H., Vogel, G., & Wasner, H. K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031362 · Cited by 1
Best Practices for Identifying and Supporting Patients who Present with PCOS
Gabrielski, A. A., Daniels, S. L., Frey, K., & Land, A. (2024) · Nursing Clinics of North America · doi:10.1016/j.cnur.2024.08.007 · Cited by 1
Expression of Serum Omentin, CTRP9, and Vaspin in Patients with Polycystic Ovary Syndrome
Wang, Y., Liu, N., Lü, J., Yang, L., Wang, C., Chen, J., & Chang, W. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1862404 · Cited by 1
“With complex pathogenesis, it is characterized by chronic anovulation and hyperandrogenism [1, 2].”
BackgroundRetractedSkin, R., & Kurzawa, M. (2021) · Aesthetic Cosmetology and Medicine · doi:10.52336/acm.2021.10.3.04
Molecular Docking Studies of Halogenated Bicyclo[4.2.0] Inositols with SARS-CoV-2 Proteins
Şahin, E. N., Karanfil, A., Şahi̇n, E., & Kelebekli, L. (2021) · Ordu Üniversitesi Bilim ve Teknoloji Dergisi · doi:10.54370/ordubtd.1015314
Oral Agents for Ovulation Induction
Narin, R. (2022) · Düzce Tıp Fakültesi Dergisi · doi:10.18678/dtfd.1185208
Polycystic Ovary Syndrome: A Comprehensive Review of Pathogenesis, Management, and Drug Regimen
Joshi, A. N., -, K. T., -, V. J., Bhatt, S. P., & Shinde, U. (2023) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2023.v05i02.2419
Khmil, S. V., Досвальд, А. С. Х., Khmil, M. S., Маланчук, Л. М., Heryak, S. M., Корда, І. В., & Bahniy, N. I. (2023) · Вісник соціальної гігієни та організації охорони здоров я України · doi:10.11603/1681-2786.2022.4.13687
Kaur, K. K., Allahbadia, G., & Singh, M. (2023) · MOJ Women s Health · doi:10.15406/mojwh.2023.12.00316
Patil, S., & Mude, G. S. (2023) · F1000Research · doi:10.12688/f1000research.135193.1
İleri Glikasyon Son Ürünleri (AGE) ve Polikistik Over Sendromu İlişkisi
AŞIK, B. N., & ÇİNTESUN, E. E. (2023) · İstanbul Sabahattin Zaim Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.47769/izufbed.1318435 · Cited by 1
(2023) · Advancement in Yoga and Physical Therapy · doi:10.33140/aypt.01.02.06
Polycystic Ovary Syndrome (PCOS) Inhibitory Drug Screening from Selective Inositols
(2023) · Toxicology and Applied Pharmacology Insights · doi:10.33140/tapi.06.01.18 · Cited by 1
Management of Polycystic Ovarian Syndrome: Looking Beyond the Ovaries
Yap‐Garcia, M. I. M. (2024) · Canadian Women s Health Today · doi:10.58931/cwht.2024.117 · Cited by 1
The Three Lichens: A Generalist Approach to Vulvar Skin Conditions
Delpero, E. (2024) · Canadian Women s Health Today · doi:10.58931/cwht.2024.1212
Cąkała, M., Zajkowska, A., Kozioł, M., Podgórniak, K., Skotnicka, J., Błaszczak, K., & Witkowska, M. (2024) · Quality in Sport · doi:10.12775/qs.2024.15.53238
Khmil, S. V., & Калник, А. А. (2024) · Актуальні питання педіатрії акушерства та гінекології · doi:10.11603/24116-4944.2024.1.14741
INOSITOL NO TRATAMENTO DA SÍNDROME DOS OVÁRIOS POLICÍSTICOS: AVALIAÇÃO DA EFICÁCIA
Rossato, D. G., Banhos, I. O., Marangoni, M. M., Maciel, M. G. D., & Nunes, Y. T. (2024) · RECIMA21 - Revista Científica Multidisciplinar · doi:10.47820/recima21.v5i9.5649
Correção da Resistência à Insulina com o Uso do Mio-inositol na Síndrome do Ovário Policístico
Marques, A. G., Richter, A. C. C., Pelegrina, A. J. S., Pacheco, I. D. A. B., Pinto, L. H., de Lima, D. D., & Schwarz, G. (2025) · Saúde Coletiva (Barueri) · doi:10.36489/saudecoletiva.2025v15i95p15552-15565 · Cited by 1
Flavonoids and Their Potential in Alleviating PCOS Symptoms: A Thorough Review
Upadhyay, S., Mazumder, A., & Das, S. (2025) · Journal of Natural Remedies · doi:10.18311/jnr/2025/49182
Albadri, H. M. B., Alrubaye, Y. S., & Abdulamir, H. A. (2025) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1764904
Salehpour, S., Hosseini, S., & Zarisfi, Z. (2025) · Obstetrics and gynecology. · doi:10.5772/intechopen.1011168
Treatment Options for Polycystic Ovary Syndrome
Cai, J., Lü, N., & Ma, J. (2025) · Obstetrics and gynecology. · doi:10.5772/intechopen.1012822 · Cited by 1
Mozafari, M., Rashidian, T., & Mirzamarjani, F. (2025) · Studies in Multidisciplinary Medical Research · doi:10.61882/smmr.202501.07.01
Ганцгорн, Е. В., Максимов, М. Л., Kechkina, V. D., Rashkova, E. V., Колесникова, Н. А., & Безбородова, Е. Д. (2025) · Фармакология & Фармакотерапия · doi:10.46393/27132129_2025_4_32-38
Greff, D., Juhász, A. E., Váncsa, S., Váradi, A., Sipos, Z., Szinte, J., Park, S., Hegyi, P., Nyírády, P., Ács, N., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22601932
Korai, A., Baba, T., Kasuga-Yamashita, F., Nagao, S., Fujibe, Y., 森下, 美., Kuno, Y., Mariya, T., Ikeda, K., Honnma, H., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0346159 · Cited by 1
“Therefore, in this study, we focused on inositol, a compound involved in insulin resistance and considered a factor in follicle development [9].”
INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH
Kabakchieva, P. (2026) · Anti-Aging Eastern Europe · doi:10.56543/aaeeu.2026.5.1.02
The stromal microenvironment of ovary: a novel area in polycystic ovary syndrome
Wang, H., Zhou, H., Liu, Z., Zhao, T., & Zhang, C. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02117-7 · Cited by 2
“Inositol may cause fewer gastrointestinal adverse events than metformin [116].”
A review of the role of physical activities in managing polycystic ovary syndrome symptoms
Orofino, F., Allibrio, E., Paternò, V., Crescimanno, C., & Pallotti, F. (2026) · Sport Sciences for Health · doi:10.1007/s11332-026-01757-y
“MI is involved in glucose uptake and FSH signaling in the ovary, while DCI influences insulin-dependent androgen synthesis [13].”
Ganjoo, A., Kalra, S., Kohli, M., Damisetty, R., Verma, S., Kandhari, R., Sharma, B., Deka, N., Beatrice, A., Pradhan, A. R., et al. (2026) · Cureus · doi:10.7759/cureus.111393
“A systematic review indicated that combining inositols with micronutrients such as FA and vitamin D may offer broader endocrine and dermatologic improvements than inositols alone [22].”
Gu, M., Wang, J., Zeng, Z., & Yu, Y. (2026) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-026-01592-3
“Polyendocrine metabolic ovarian syndrome (PMOS) is a complex and heterogeneous endocrine disorder that affects approximately 10–15% of women of reproductive age worldwide, serving as a primary driver of anovulatory infertility [1, 2].”
He, Q., Yan, W.-H., Li, Y.-B., Hong, W.-B., Xin-Rong, H. E., Huang, Y.-X., Zheng, F.-P., Yang, Z.-B., & Chen, X. (2026) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2026.10.001
Metadata
- Authors
- Kamenov, Z., & Gateva, A.
- Affiliations
- Alexandrovska Hospital (BG)
- Corresponding author
- Kamenov, Zdravko
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-11-27
- Volume
- 25
- Issue
- 23
- Pages
- 5566
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7729761
- OpenAlex
- W3109824023
- Cited by
- 100
- References
- 147
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 15 · 2023: 29 · 2022: 14 · 2021: 12
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Biology and Fertility
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Keywords
- polycystic ovary syndrome, myo-inositol, D-chiro-inositol, insulin resistance, hyperandrogenism, hirsutism, acne, ovulation induction, ovarian function, fertility, insulin signaling, metabolic outcomes
- MeSH terms
- Animals, Female, Humans, Inositol, Ovulation, Polycystic Ovary Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.